Abstract
We examined the existence of a relationship between polymorphism and dementia in subjects aged 90 years and above. The sample included 732 unrelated Chinese nonagenarians/centenarians (aged 90–108 years, mean age 93.68 years; 67.5% women). The Pro12Ala variant was examined using polymerase chain reaction restriction fragment length polymorphism. Cognitive function was measured with 30-item mini-mental state examination. The genotype frequencies of the Pro12Ala polymorphism were 0% Ala12Ala, 9.1% Pro12Ala, and 90.9% Pro12Pro. The prevalence rates of dementia were 64.9% in the whole sample (45.0% for men and 74.5% for women). In both men and women, between subjects with and without 12Ala carriers, there was no significant difference in cognitive function scores and also no significant difference in prevalence of dementia; there was no significant difference in frequency of 12Ala carriers between subjects with and without dementia. Multiple logistic regression was performed by adjusting clinical factors that are thought to be associated with cognitive function or with 12Ala carriers. We found that 12Ala is not a risk factor for dementia. We found that Pro12Ala polymorphism in PPAR-γ2 was not directly correlated with dementia among Chinese nonagenarians and centenarians.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barbieri M, Bonafe M, Rizzo MR, Ragno E, Olivieri F, Marchegiani F, Franceschi C, Paolisso G (2004) Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp Gerontol 39:1095–1100
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435
Chuang LM, Hsiung CA, Chen YDI, Ho LT, Sheu WHH, Pei D, Nakatsuka CH, Cox D, Pratt RE, Lei HH, Tai TY (2001) Sibling-based association study of the PPAR gamma(2) Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. J Mol Med 79:656–664
Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH (2008) Prevalence of dementia after age 90: results from the 90+ study. Neurology 71:337–343
Dahlman I, Arner P (2007) Obesity and polymorphisms in genes regulating human adipose tissue. Int J Obes 31:1629–1641
Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312–4317
Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650
Jama JW, Launer LJ, Witteman JC, den Breeijen JH, Breteler MM, Grobbee DE, Hofman A (1996) Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam study. Am J Epidemiol 144:275–280
Johnson W, Harris SE, Starr JM, Whalley LJ, Deary IJ (2008) PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes. Neurosci Lett 434:50–55
Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 32:845–856
Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819
Langley LK (2000) Cognitive assessment of older adults. In: Kane RL (ed) Assessing older persons. Oxford University Press, Oxford, pp 65–128
Masud S, Ye S, Group SAS (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40:773–780
McIntyre RS, Soczynska JK, Woldeyohannes HO, Lewis GF, Leiter LA, MacQueen GM, Miranda A, Fulgosi D, Konarski JZ, Kennedy SH (2007) Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 8:1615–1628
Meirhaeghe A, Boreham CA, Murray LJ, Richard F, Davey Smith G, Young IS, Amouyel P (2007) A possible role for the PPARG Pro12Ala polymorphism in preterm birth. Diabetes 56:494–498
Poorkaj P, Grossman M, Steinbart E, Payami H, Sadovnick A, Nochlin D, Tabira T, Trojanowski JQ, Borson S, Galasko D, Reich S, Quinn B, Schellenberg G, Bird TD (2001) Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 58:383–387
Santos MJ, Quintanilla RA, Toro A, Grandy R, Dinamarca MC, Godoy JA, Inestrosa NC (2005) Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem 280:41057–41068
Scacchi R, Pinto A, Gambina G, Rosano A, Corbo RM (2007) The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res 1139:1–5
Silberfeld M, Rueda S, Krahn M, Naglie G (2002) Content validity for dementia of three generic preference based health related quality of life instruments. Qual Life Res 11:71–79
Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507–514
Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, Ordovas JM (2004) Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 45:674–685
Tombaugh TN, McIntyre NJ (1992) The mini-mental state exam: a comprehensive review. J Am Geriatr Soc 40:922–935
Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147–1156
Watson GS, Craft S (2003) The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17:27–45
Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950–958
West NA, Haan MN, Morgenstern H (2008) The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2008.06.005
Yaffe K, Kanaya AM, Lindquist K, Hsueh WC, Cummings SR, Beamer B, Newman A, Rosano C, Li R, Harris T (2008) PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol Aging 29:78–83
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270–274
Acknowledgments
This work was supported by the Discipline Construction Foundation of Sichuan University and by grants from the Project of Science and Technology Bureau of Sichuan Province (2006Z09-006-4) and the Construction Fund for Subjects of West China Hospital of Sichuan University (XK05001). The authors thank the staff of the Department of Geriatrics Medicine, West China Hospital, Dujiangyan Government and Dujjiangyan People’s Hospital and all participants (as well as their legal proxies) for their great contribution. Dr. Joey Kwong is especially acknowledged for language assistance.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ji-Rong, Y., Bi-Rong, D., Chang-Quan, H. et al. Pro12Ala polymorphism in PPAR-γ2 and dementia in Chinese nonagenarians/centenarians. AGE 32, 397–404 (2010). https://doi.org/10.1007/s11357-010-9132-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-010-9132-1